Table 6.
RESPONSE | GIMEMA 2019 | NCCN 2019 | ELN 2020 | |
---|---|---|---|---|
3 months | Optimal | ≤ 10 | ≤ 10 | ≤ 10 |
Warning | - | > 10 | > 10 | |
Failure | > 10 (confirmed) | - | - | |
6 months | Optimal | ≤ 1 | ≤ 10 | ≤ 1 |
Warning | 1-10 | – | 1-10 | |
Failure | > 10 | > 10 | > 10 | |
12 months | Optimal | ≤ 0.1 | ≤ 1 | ≤ 0.1 |
Warning | 0.1-1 | 1-10 | 0.1-1 | |
Failure | > 1 | > 10 | > 1 | |
24 months | Optimal | ≤ 0.01 | ≤ 1 | ≤ 0.1 |
Warning | 0.1-0.01 | – | 0.1-1 | |
Failure | > 0.1 | > 1 | > 1 |
GIMEMA Gruppo Italiano Malattie EMatologiche dell'Adulto, ELN European LeukemiaNet, NCCN National Comprehensive Cancer Network